Article
Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir.
Antiviral research - 1 Apr 1999
Oon C J, Chen W N, Lim N, Koh S, Lim G K, Leong A L, Tan G S
Abstract excerpt
Lamivudine is a new antiviral agent effective against hepatitis B viral (HBV) infections but can result in virus-drug resistance associated with mutations in the conserved 'YM552DD' motif of the HBV DNA polymerase. Due to their overlapping coding regions in the HBV genome, mutations in the DNA polymerase may result in substitutions in the hepatitis B surface antigen (HBsAg), albeit outside the antigenic 'a'...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
